Breyanzi >= 5.1 x 10^6 cellen [CD8 component]
As listed in the register: Breyanzi >= 5.1 x 10^6 cellen [CD8 component], suspensie voor injectie
· suspensie voor injectie
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Lisocabtageen Maraleucel (Cd8+ Component)
- Made by
- Celgene Europe B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Celgene Europe B.V. |
|---|---|
| Active substance | Lisocabtageen Maraleucel (Cd8+ Component) |
| Used in | Cancer treatments and immune-system medicines |
| Form | suspensie voor injectie |
| Classification | L01XL08 · Cancer treatments and immune-system medicines |
| Route | intraveneus gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| Name in the register | Breyanzi >= 5.1 x 10^6 cellen [CD8 component], suspensie voor injectie |
| RVG | EU/1/22/1631 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).